Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Sorafenib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-10-20

Last Posted Date: 2014-12-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 85

Registration Number: NCT00390611

Locations: 🇺🇸
Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Holy Cross Hospital, Ft. Lauderdale, Florida, United States

and more 14 locations

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Phase 1

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: Pazopanib
Drug: paclitaxel
Drug: Lapatinib
Drug: carboplatin

First Posted Date: 2006-10-13

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 86

Registration Number: NCT00388076

Locations: 🇺🇸
GSK Investigational Site, Nashville, Tennessee, United States

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

Phase 2

Completed

Conditions: Drug/Agent Toxicity by Tissue/Organ
Stage IIIB Non-small Cell Lung Cancer
Adenosquamous Cell Lung Cancer
Hemoptysis
Squamous Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Biological: bevacizumab
Drug: paclitaxel
Drug: carboplatin
Radiation: radiation therapy

First Posted Date: 2006-10-13

Last Posted Date: 2013-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT00387374

Locations: California Cancer Consortium

A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients

Phase 2

Conditions: Endometrial Cancer

First Posted Date: 2006-09-08

Last Posted Date: 2006-09-08

Lead Sponsor: Korean Gynecologic Oncology Group

Target Recruit Count: 50

Registration Number: NCT00373620

Locations: 🇰🇷
Young-Dong Severance Hospital, Seoul, Korea, Republic of

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

Phase 3

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Sunitinib
Drug: bevacizumab
Drug: paclitaxel

First Posted Date: 2006-09-08

Last Posted Date: 2012-09-10

Lead Sponsor: Pfizer

Target Recruit Count: 488

Registration Number: NCT00373256

Locations: 🇪🇸
Pfizer Investigational Site, Madrid, Spain

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 2

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Biological: MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine
Biological: tetanus toxoid helper peptide
Drug: carboplatin
Drug: paclitaxel
Procedure: conventional surgery

First Posted Date: 2006-09-07

Last Posted Date: 2022-09-21

Lead Sponsor: Craig L Slingluff, Jr

Target Recruit Count: 6

Registration Number: NCT00373217

Locations: 🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Phase 2

Terminated

Conditions: Advanced Non-squamous NSCLC

Interventions: Biological: Bevacizumab
Drug: AMG 706
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2006-08-29

Last Posted Date: 2018-01-04

Lead Sponsor: Amgen

Target Recruit Count: 186

Registration Number: NCT00369070

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Adenocarcinoma of the Lung
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Stage II Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Radiation: 3-dimensional conformal radiation therapy
Drug: paclitaxel
Biological: bevacizumab
Drug: carboplatin
Other: laboratory biomarker analysis

First Posted Date: 2006-08-29

Last Posted Date: 2014-03-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00369551

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

Phase 1

Completed

Conditions: Stage IIIC Breast Cancer
Stage IIIB Breast Cancer
Male Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: vorinostat
Drug: paclitaxel
Biological: bevacizumab

First Posted Date: 2006-08-29

Last Posted Date: 2015-11-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT00368875

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Lung
Adenosquamous Cell Lung Cancer
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Biological: cetuximab
Drug: paclitaxel
Biological: bevacizumab

First Posted Date: 2006-08-29

Last Posted Date: 2015-09-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 110

Registration Number: NCT00368992

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy